OakChart

Sonoma Pharmaceuticals Inc

SNOAHealthcare·Drug Manufacturers - Specialty & Generic·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.24+0.10 (8.77%)
2026-11-12 03:47 CET
Market cap
5.94 USD m
Revenue, TTM
23.49 USD m
Net income, TTM
-1.80 USD m
Free cash flow, TTM
-2.79 USD m
EPS diluted, TTM
-0.91
P/E
-
Compare

Price

SNOA against its 20, 50 and 200-day averages
2050200earnings
1.002.003.00765K1.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SNOAclose 1.2420-day 1.1350-day 1.21200-day 1.621.24

68.6% under the 52-week high of 3.95 on 11 Dec 2025. 52-week low 0.85 on 24 Apr 2026. Last 15 sessions, 23.7% high to low

Volume 5.60× normal · the line is the 50-bar volume average

Profile

SNOA
52-week range, 13% of the way up
0.853.95

Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. Its products are used for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.

Employees259
IPOJan 25, 2007
Beta1.30
ATR, 14d0.08
Rel volume5.60
Short float1.40%
Insider own0.44%
Inst own2.82%

Snapshot

6 groups

Valuation

Index-
Market Cap5.94M
Enterprise Value1.93M
Income-1.80M
Sales23.49M
Book/sh1.31
Cash/sh0.96
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees259
IPOJan 25, 2007

Ratios

P/E-
Forward P/E-
PEG-
P/S0.25
P/B0.95
P/C1.29
P/FCF-
EV/EBITDA-
EV/Sales0.08
Quick Ratio2.68
Current Ratio3.48
Debt/Eq0.09
LT Debt/Eq0.06
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.91
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y60.40% 47.50%
Sales past 3/5Y13.74% 0.95%
EPS Y/Y TTM58.68%
Sales Y/Y TTM38.69%
EPS Q/Q95.87%
Sales Q/Q28.02%
EarningsNov 10 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own0.44%
Insider Trans0.00%
Inst Own2.82%
Inst Trans1.06%
ROA-11.60%
ROE-34.54%
ROIC-25.67%
Gross Margin39.23%
Oper. Margin-3.32%
Profit Margin-7.65%
SMA209.30%
SMA502.61%
SMA200-23.23%
Trades-

Technical

Shs Outstand5.06M
Shs Float4.77M
Short Float1.40%
Short Ratio1.15
Short Interest0.07M
52W High3.95 -68.61%
52W Low0.85 45.87%
Volatility7.73% 6.61%
ATR (14)0.08
RSI (14)59.13
Beta1.30
Rel Volume5.60
Avg Volume57.91K
Volume324,222

Performance

Perf Week11.71%
Perf Month5.08%
Perf Quarter-7.46%
Perf Half Y7.83%
Perf YTD-65.93%
Perf Year-66.80%
Perf 3Y-55.90%
Perf 5Y-98.91%
Perf 10Y-99.85%
Recom1.00
Target Price12.00
Prev Close1.14
Price1.24
Change %8.77%

Peers

Mkt cap
TickerCompanyMkt cap
BFRIBiofrontera Inc13.92M
SMTISanara MedTech Inc290.43M
NXGLNexgel Inc13.03M
CUPRCuprina Holdings (Cayman) Ltd10.13M
ORGOOrganogenesis Holdings Inc136.29M
YCBDcbdMD Inc4.43M
DERMJourney Medical Corp125.31M
SNWVSanuwave Health Inc15.31M
MDXGMimedx Group Inc484.47M
RCELAVITA Medical Inc429.73M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax (ACCESSWIRE) +8.77%
  • Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA (ACCESSWIRE) +10.62%
  • Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution (ACCESSWIRE)
  • Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results (ACCESSWIRE)
  • Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering (ACCESSWIRE) -36.67%
  • Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart (ACCESSWIRE) -8.24%
  • Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin (ACCESSWIRE)
  • Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results (ACCESSWIRE)
  • Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development (ACCESSWIRE)
  • National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced (ACCESSWIRE)
  • Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Dusseldorf (ACCESSWIRE)
  • Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results (ACCESSWIRE)
  • Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals (ACCESSWIRE)
  • Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-11-100.095--0.0137.17--
2026Q12026-08-060.015--0.0866.41--
2025Q32026-02-10-0.352-0.290-0.4784.355.471
2025Q22025-11-04-0.129--0.3245.60--
2025Q12025-08-07-0.369-0.510-0.7564.024.051
2024Q42025-06-17-0.152--0.4793.75--
2024Q32025-02-05-0.595-0.690-0.6343.564.061
2024Q22024-11-07-0.618-0.800-0.5903.583.821
2024Q12024-08-13-1.265-1.000-1.3423.393.782
2023Q42024-06-17-1.378--1.3673.44--
2023Q32024-02-09-1.196--1.5883.14--
2023Q22023-11-14-3.982-3.776-5.7472.733.602
2023Q12023-08-10-5.800-2.400-5.7463.433.381
2022Q42023-06-22-4.682--5.5923.013.30-
2022Q32023-02-14-12.400--12.4812.94--
2022Q22022-11-14-6.600--6.5593.33--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2013FY-600.31-51648613.6714.29
2014FY-765-949.5-76513.8513.05
2015FY-558-549-2,78115.0815.05
2016FY390.6376.2-443.3912.8314.57
2017FY-568.8-515.7-569.3216.6617.40
2018FY-210.21-255.4-255.3718.9719.00
2022FY-21.838-24.800-30.35413.2713.56
2023FY-7.694--10.63812.74-
2024FY-2.251--2.78614.29-
2025FY-1.890--1.89019.53-
2026FY--0.560--23.91
2027FY-0.070--26.95

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q2S2025-10-021005.295.295.29
2026Q2S2025-10-011005.295.295.29
2026Q2S2025-09-301005.295.295.29
2026Q2S2025-09-291005.295.295.29
2026Q2S2025-09-281005.295.295.29
2026Q2S2025-09-271005.295.295.29
2026Q2S2025-09-261005.295.295.29
2026Q2S2025-09-251005.295.295.29
2026Q2S2025-09-241005.295.295.29
2026Q2S2025-09-231005.295.295.29
2026Q2S2025-09-221005.295.295.29
2026Q2S2025-09-211005.295.295.29
2026Q2S2025-09-201005.295.295.29
2026Q2S2025-09-191005.295.295.29

Estimate history

EPS, annual-569.324-255.368-44.794-47.295-38.342-30.354-10.638-2.786-1.885-0.9066
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.59-0.634-0.479-0.756-0.324-0.478-0.329-0.086-0.013
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual16.65818.9717.92818.62912.62813.27212.73514.28819.52923.49
Period201720182019202020212022202320242025TTM
Sales, quarterly3.5793.5643.7544.0155.6044.3495.5616.4067.174
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0340.0660.0890.1050.1550.2470.781.6341.7995.058
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.3391.6161.6341.6431.651.7311.7994.7865.058
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue23.4919.5314.2912.7313.2712.6318.6317.9318.97
Cost of Goods Sold Incl. D&A14.2812.118.827.998.798.6312.079.8110.09
Gross Profit9.217.425.464.754.483.996.568.128.88
Selling, General and Administrative Excl. Other9.999.889.189.459.059.8810.0115.5120.14
Research and Development2.172.271.811.870.210.120.561.341.52
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-0.78-2.46-3.71-4.70-4.57-5.89-3.45-7.39-11.26
Interest Expense-----0.010.010.020.03
Unusual Expense0.000.000.000.000.00-0.720.000.00-
Net Income Before Taxes-1.39-3.42-2.91-5.03-5.18-5.42-3.90-3.54-11.34
Income Taxes0.40-0.240.55-0.20-0.03-0.330.710.030.46
Consolidated Net Income-1.80-3.17-3.46-4.83-5.15-5.09-4.62-3.57-11.80
Net Income From Continuing Operations-1.80-3.17-3.46-4.83-5.15-5.09-4.62-3.57-11.80
Net Income-1.80-3.17-3.46-4.83-5.15-5.09-4.72-3.31-11.80
EPS (Recurring)-0.37-1.89-2.79-10.64-30.35-42.16-47.29-44.79-255.37
EPS (Basic, Before Extraordinaries)-0.91-1.89-2.79-10.64-30.35-38.34-47.29-44.79-255.37
EPS (Diluted)-0.91-1.89-2.79-10.64-30.35-38.34-47.29-44.79-255.37
EBITDA-0.65-2.32-3.57-4.53-4.27-5.48-3.22-7.08-10.80
Non-Operating Income (Expense)-0.61-0.960.80-0.33-0.61-0.24-0.443.86-0.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.260.200.180.410.530.300.370.841.15
Price To Sales Ratio0.270.180.190.120.250.840.800.400.41
Gross Margin39.2337.9738.2537.2633.7331.6235.2145.3046.81
Operating Margin-3.32-12.60-25.97-36.91-34.43-46.62-18.51-41.22-59.35
Net Margin-7.65-16.26-24.20-37.97-38.81-40.28-25.34-18.45-62.19
Shares Outstanding5.061.801.630.780.250.160.100.090.07
Market Capitalization5.945.943.542.284.8212.4315.558.7111.26

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue7.176.415.564.355.604.013.753.56
Cost of Goods Sold Incl. D&A4.373.833.382.703.482.552.232.29
Gross Profit2.812.582.181.652.121.461.531.27
Selling, General and Administrative Excl. Other2.522.622.532.332.462.562.182.30
Research and Development0.470.600.550.560.570.590.410.43
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income0.29-0.04-0.35-0.68-0.34-1.09-0.66-1.03
Interest Expense-------0.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes0.38-0.33-0.50-0.95-0.73-1.24-0.53-0.92
Income Taxes0.450.000.08-0.13-0.20-0.000.250.01
Consolidated Net Income-0.07-0.33-0.58-0.82-0.53-1.24-0.78-0.93
Net Income From Continuing Operations-0.07-0.33-0.58-0.82-0.53-1.24-0.78-0.93
Net Income-0.07-0.33-0.58-0.82-0.53-1.24-0.78-0.93
EPS (Recurring)-0.01-0.09-0.33-0.48-0.32-0.76-0.48-0.63
EPS (Basic, Before Extraordinaries)-0.01-0.09-0.33-0.48-0.32-0.76-0.48-0.63
EPS (Diluted)-0.01-0.09-0.33-0.48-0.32-0.76-0.48-0.63
EBITDA0.32-0.01-0.32-0.64-0.30-1.06-0.62-1.00
Non-Operating Income (Expense)0.09-0.29-0.15-0.27-0.39-0.150.130.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.080.060.110.020.030.050.070.01
Price To Sales Ratio0.270.220.190.350.380.310.250.28
Gross Margin39.1340.2339.2237.9437.8336.4640.7035.63
Operating Margin4.04-0.62-6.31-15.59-6.01-27.27-17.47-28.93
Net Margin-0.92-5.15-10.45-18.83-9.53-30.91-20.67-26.04
Shares Outstanding5.064.791.801.731.651.641.631.62
Market Capitalization5.945.893.696.196.384.673.543.60

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments2.405.373.133.827.404.223.693.6910.07
Short Term Receivables2.532.232.902.572.412.813.973.481.54
Inventories3.652.922.722.862.662.532.183.412.87
Other Current Assets3.441.923.544.313.753.222.261.691.55
Total Current Assets12.0112.4412.2913.5616.2112.7712.1012.2716.02
Net Property, Plant & Equipment0.910.310.650.910.881.130.720.731.14
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Deferred Tax Assets0.990.691.301.131.17----
Other Assets0.150.360.660.820.931.081.741.452.06
Total Assets14.0713.7914.8916.4119.1814.9914.5614.4519.21
Short Term Debt Incl. Current Port. of LT Debt0.370.280.520.691.060.840.610.460.38
Accounts Payable1.920.950.610.841.641.772.071.251.27
Income Tax Payable--------0.00
Other Current Liabilities2.542.872.592.193.121.472.051.871.61
Total Current Liabilities4.834.103.723.725.824.084.733.593.26
Long Term Debt0.470.030.090.160.311.840.230.010.18
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.110.100.150.180.34----
Other Liabilities5.565.164.804.384.023.713.970.360.44
Total Liabilities10.989.388.768.4310.499.628.943.963.88
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity3.104.416.147.988.705.365.6210.4915.33
Total Shareholders Equity3.104.416.147.988.705.365.6210.4915.33
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity3.104.416.147.988.705.365.6210.4915.33
Total Liabilities & Stockholders Equity14.0713.7914.8916.4119.1814.9914.5614.4519.21
Book Value Per Share1.722.707.8632.3456.0951.2563.28159.37446.99
Tangible Book Value Per Share1.722.707.8632.3456.0951.2563.28159.37446.99
Full-Time Employees259168172171177198298254217
Price to Book Ratio0.950.730.340.601.432.901.000.841.20
Return on Assets-22.79-24.10-30.89-28.94-29.77-31.24-24.63-70.11-64.16
Return on Equity-84.60-65.55-68.51-61.78-72.35-65.61-44.35-91.40-77.96
Return on Invested Capital-89.09-77.90-77.68-63.29-56.47-65.54-56.46-112.35-92.43
Quick Ratio1.732.322.572.882.332.512.102.474.03
Current Ratio2.493.043.303.652.793.132.563.424.91

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-1.80-3.17-3.46-4.83-5.15-5.09-3.95-3.31-11.80
Depreciation0.130.140.140.180.300.410.230.310.45
Other Funds (Non Cash)0.27-0.260.400.680.60-1.87-1.04-0.400.89
Funds from Operations-1.77-3.53-2.56-4.09-4.29-7.38-4.76-3.39-10.45
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.90-0.412.481.69-1.863.131.38-1.20-1.27
Income Taxes Payable0.340.42-------
Cash from Operating Activities-2.67-3.93-0.09-2.40-6.15-4.25-3.38-4.59-11.72
Capital Expenditures-0.12-0.19-0.08-0.02-0.27-0.14-0.18-0.21-0.10
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00-0.040.00-0.03
Other Sources0.000.000.000.010.010.040.613.850.00
Cash from Investing Activities-0.12-0.19-0.08-0.00-0.26-0.100.393.64-0.13
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock4.280.473.161.782.877.772.291.385.70
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock4.280.473.161.782.877.772.291.385.70
Proceedsfrom Stock Options4.280.433.081.782.877.550.001.385.70
Issuance or Reduction of Debt, Net-0.27-0.27-0.40-0.48-0.38-0.371.02-0.35-0.48
Change in Long Term Debt0.000.000.000.000.00-0.471.02-0.35-0.48
Issuance of Long Term Debt0.000.000.000.000.000.001.500.000.00
Reduction of Long Term Debt0.000.000.000.000.00-0.47-0.48-0.35-0.48
Net Financing Active Other Cash Flow0.280.280.270.370.000.000.000.000.27
Other Financing Activities Uses0.000.00-0.000.000.000.000.000.00-
Cash from Financing Activities4.280.483.031.682.497.403.311.035.49
Exchange Rate Effect0.080.67-0.620.030.340.130.21-0.08-0.02
Net Change in Cash1.57-2.982.25-0.69-3.583.180.530.00-6.38
Free Cash Flow-2.79-4.12-0.17-2.42-6.42-4.38-3.56-4.80-11.82
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit--0.230.36-0.11-0.04-0.830.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments4.615.342.402.563.043.60
Short Term Receivables3.583.182.532.382.702.60
Inventories3.513.793.653.703.633.80
Other Current Assets3.643.963.443.352.922.87
Total Current Assets15.3416.2712.0112.0012.3012.88
Net Property, Plant & Equipment0.820.870.910.960.760.84
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets0.880.910.990.460.510.55
Other Assets0.060.070.150.210.290.33
Total Assets17.1018.1114.0713.6213.8614.59
Short Term Debt Incl. Current Port. of LT Debt0.220.300.370.150.140.23
Accounts Payable1.552.191.921.651.402.05
Other Current Liabilities2.642.962.542.422.772.57
Total Current Liabilities4.425.454.834.224.324.85
Long Term Debt0.380.440.470.510.390.44
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.11---
Other Liabilities5.695.635.565.465.365.25
Total Liabilities10.4911.5110.9810.1910.0710.54
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity6.616.593.103.433.794.06
Total Shareholders Equity6.616.593.103.433.794.06
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity6.616.593.103.433.794.06
Total Liabilities & Stockholders Equity17.1018.1114.0713.6213.8614.59
Book Value Per Share1.311.381.721.982.302.47
Tangible Book Value Per Share1.311.381.721.982.302.47
Full-Time Employees--259---
Price to Book Ratio0.950.711.071.591.571.05
Return on Assets-11.60-13.85-22.79-24.70-25.26-25.15
Return on Equity-34.54-42.52-84.60-81.19-76.14-78.73
Return on Invested Capital-0.94-4.69-16.30-20.78-12.78-27.60
Quick Ratio2.682.291.731.972.001.87
Current Ratio3.482.992.492.842.852.66

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-0.07-0.33-0.58-0.82-0.53-1.24
Depreciation0.030.030.030.030.040.04
Other Funds (Non Cash)0.130.100.17-0.140.10-0.39
Funds from Operations0.10-0.20-0.81-0.86-0.35-1.50
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.83-0.450.290.10-0.28-0.51
Income Taxes Payable0.070.060.100.110.110.10
Cash from Operating Activities-0.74-0.65-0.52-0.76-0.64-2.02
Capital Expenditures-0.04-0.00-0.03-0.05-0.01-0.11
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.04-0.00-0.03-0.05-0.01-0.11
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.323.540.160.270.020.02
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.323.540.160.270.020.02
Proceedsfrom Stock Options0.313.540.160.270.000.00
Issuance or Reduction of Debt, Net-0.08-0.08-0.05-0.06-0.08-0.08
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.280.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.233.450.390.21-0.06-0.06
Exchange Rate Effect-0.180.14-0.000.130.140.41
Net Change in Cash-0.732.94-0.16-0.47-0.57-1.77
Free Cash Flow-0.78-0.65-0.55-0.81-0.65-2.12

Revenue breakdown

Product2024: 13.73M
Service2024: 556.00K
Total Surgical & Medical Instruments & Apparatus revenue2025: 19.53M
Asia2024: 2.32M 2025: 2.90M
Europe2024: 5.52M 2025: 6.90M
Latin America2024: 2.96M 2025: 2.37M
Rest Of The World2024: 875.00K 2025: 1.68M
United States2024: 2.61M 2025: 5.67M
Animal Care2024: 1.65M 2025: 1.85M
Human Care2024: 12.64M 2025: 17.68M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.40%0.1M4.8M106.77K
2026-10-152.28%0.1M4.8M105.35K
2026-09-303.45%0.2M4.8M113.88K
2026-09-154.22%0.2M4.8M150.22K
2026-08-313.82%0.2M4.8M157.31K
2026-08-144.21%0.2M4.8M172.63K
2026-07-310.18%0.0M4.8M124.66K
2026-07-151.05%0.0M4.8M247.43K
2026-06-301.74%0.1M4.8M235.41K
2026-06-150.10%0.0M4.8M195.86K
2026-05-291.32%0.0M3.4M184.66K
2026-05-150.79%0.0M3.4M161.32K
2026-04-3043.70%0.8M1.7M148.34K
2026-04-150.94%0.0M1.7M23.40K
2026-03-312.28%0.0M1.7M21.08K
2026-03-130.77%0.0M1.7M17.54K
2026-02-270.76%0.0M1.7M19.20K
2026-02-131.07%0.0M1.7M21.19K
2026-01-301.51%0.0M1.7M22.78K
2026-01-151.69%0.0M1.7M26.16K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-068-A12B/ASEC
2026-10-068-KCurrent report2026-10-06SEC
2026-09-178-KCurrent report2026-09-16SEC
2026-08-198-KCurrent report2026-08-19SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-16SEC
2026-07-23DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-09S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-24DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-06-188-KCurrent report2026-06-18SEC
2026-06-18424B5SEC
2026-06-1610-KAnnual report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-05DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-24SEC
2026-04-308-KCurrent report2026-04-24SEC
2026-04-27424B4SEC
2026-04-27PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-24SEC
2026-04-23EFFECTEffectiveness filing by commission orderSEC
2026-04-23S-1/ASEC
2026-04-22CORRESPSEC
2026-04-22CORRESPSEC
2026-04-17S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-04-10UPLOADUpload SubmissionSEC
2026-04-09DRSSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
GEODE CAPITAL MANAGEMENT, LLC1.16%
RENAISSANCE TECHNOLOGIES LLC0.85%
VANGUARD CAPITAL MANAGEMENT LLC0.39%
McKinley Carter Wealth Services, Inc.0.23%
UBS Group AG0.13%
Global Retirement Partners, LLC0.05%
MORGAN STANLEY0.04%
OSAIC HOLDINGS, INC.0.01%
BARCLAYS PLC0.01%
BlackRock, Inc.0.00%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.43%
VANGUARD EXTENDED MARKET INDEX FUND0.39%
Fidelity Total Market Index Fund0.05%
Fidelity Series Total Market Index Fund0.05%

OakChart. SNOA. Cached 15 minutes.

Some panels did not load: ratings, insider.